UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 130

Sortiert nach

Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

Journal of clinical oncology, 2010-01, Vol.28 (1), p.92-98

2010

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive molecular profiling identifies actionable biomarkers for patients from Thailand and the United Arab Emirates with advanced malignancies

Frontiers in oncology, 2024, Vol.14, p.1374087-1374087

2024

Link zum Volltext

Verfügbarkeit prüfen

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report

Case reports in oncology, 2023-01, Vol.16 (1), p.1451-1459

2023

Link zum Volltext

Verfügbarkeit prüfen

Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women

Clinical cancer research, 2011-04, Vol.17 (7), p.1867-1874

2011

Link zum Volltext

Verfügbarkeit prüfen

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

Clinical cancer research, 2009-12, Vol.15 (23), p.7381-7388

2009

Link zum Volltext

Verfügbarkeit prüfen

Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4891-4898

2008

Link zum Volltext

Verfügbarkeit prüfen

Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study

Breast cancer research and treatment, 2011-02, Vol.126 (1), p.185-192

2011

Link zum Volltext

Verfügbarkeit prüfen

Triple-Negative Breast Cancer: Epidemiology and Management Options

Drugs (New York, N.Y.), 2010-01, Vol.70 (17), p.2247-2258

Dawood, Shaheenah

2010

Link zum Volltext

Verfügbarkeit prüfen

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer

Cancers, 2023-09, Vol.15 (18), p.4558

2023

Link zum Volltext

Verfügbarkeit prüfen

Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India

JCO global oncology, 2024-03, Vol.10 (10), p.e2300330-e2300330

2024

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer

Journal of clinical oncology, 2009-07, Vol.27 (20), p.3303-3311

2009

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings

Breast cancer research and treatment, 2008-06, Vol.109 (3), p.417-426

2008

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer

Clinical cancer research, 2008-03, Vol.14 (6), p.1718-1725

2008

Link zum Volltext

Verfügbarkeit prüfen

Cancer stem cells: implications for cancer therapy

Oncology (Williston Park, N.Y.), 2014-12, Vol.28 (12), p.1101-1110

2014

Link zum Volltext

Verfügbarkeit prüfen

Use of PARPi among patients with HER2+ve MBC: Results from a real world dataset

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13044-e13044

2023

Link zum Volltext

Verfügbarkeit prüfen

Impact of use of CDK4/6i and neratinib among patients with HER2 +ve MBC: Results from a real world dataset

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13046-e13046

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-world PARPi treatment patterns and outcomes among patients with metastatic breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13005-e13005

2022

Link zum Volltext

Verfügbarkeit prüfen

Use of RET inhibitors among patients with advanced NSCLC: A real-world evidence analysis

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9079-9079

2022

Link zum Volltext

Verfügbarkeit prüfen

Triple Receptor–Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes

Journal of clinical oncology, 2009-01, Vol.27 (2), p.220-226

2009

Link zum Volltext

Verfügbarkeit prüfen

Comparison of biomarkers among 34,855 GI cancer samples show heterogeneity of tumor types

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14287-e14287

Dawood, Shaheenah S.

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparison of biomarkers among 34855 GI cancer samples shows heterogeneity of tumor types

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.217-217

Dawood, Shaheenah S.

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of CDK4/6i in the visceral crisis setting: Result from a real-world database

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1047-1047

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of race on the utilization and efficacy of CDK4/6i: Result from a real world database

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e13036-e13036

2021

Link zum Volltext

Verfügbarkeit prüfen

Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting

BMC proceedings, 2021-08, Vol.15 (Suppl 10), p.15-15, Article 15

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacology and Pharmacogenetics of Chemotherapeutic Agents

Cancer investigation, 2009-01, Vol.27 (5), p.482-488

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 130

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Englisch
(130)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

Comprehensive molecular profiling identifies actionable biomarkers for patients from Thailand and the United Arab Emirates with advanced malignancies

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report

Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer

Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study

Triple-Negative Breast Cancer: Epidemiology and Management Options

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer

Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India

Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer

Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings

Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer

Cancer stem cells: implications for cancer therapy

Use of PARPi among patients with HER2+ve MBC: Results from a real world dataset

Impact of use of CDK4/6i and neratinib among patients with HER2 +ve MBC: Results from a real world dataset

Real-world PARPi treatment patterns and outcomes among patients with metastatic breast cancer

Use of RET inhibitors among patients with advanced NSCLC: A real-world evidence analysis

Triple Receptor–Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes

Comparison of biomarkers among 34,855 GI cancer samples show heterogeneity of tumor types

Comparison of biomarkers among 34855 GI cancer samples shows heterogeneity of tumor types

Efficacy of CDK4/6i in the visceral crisis setting: Result from a real-world database

Impact of race on the utilization and efficacy of CDK4/6i: Result from a real world database

Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting

Pharmacology and Pharmacogenetics of Chemotherapeutic Agents

Suchergebnisse filtern